Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 3/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 5/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6784875 | 0.83 | F2 (0.39) | F2PRSS1PRSS2PRSS3CRBN | |
| SCHEMBL144642 | 0.75 | LMNA (0.47) | F2PRSS1PRSS2PRSS3CA2 | |
| SCHEMBL6789519 | 0.69 | CA2 (0.45) | CRBNCA2CA1KMT2ACDK2 | |
| SCHEMBL6594256 | 0.68 | TSHR (0.38) | CA2MAOAMAPT | |
| SCHEMBL8302470 | 0.67 | CA2 (0.39) | CRBNCA2KMT2AMAOATDP1 | |
| SCHEMBL8647854 | 0.67 | MMP2 (0.34) | F2PRSS1PRSS2PRSS3CRBN | |
| SCHEMBL8304958 | 0.65 | GAA (0.36) | CRBNCA2KMT2AMAPT | |
| SCHEMBL444871 | 0.65 | MMP2 (0.50) | F2PRSS1PRSS2PRSS3CA2 | |
| SCHEMBL6789143 | 0.64 | CRBN (0.47) | CRBNCA2KMT2AMAOATDP1 | |
| SCHEMBL644453 | 0.62 | HTR2A (0.51) | CA2CA1MMP2MMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12209144-B2 | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2025-01-28 | — | — | US | disclosed |
| US-20240036046-A1 | CANCER EXAMINATION METHOD AND CANCER TREATMENT AGENT | IMAMITSUKAI MEDICAL CORPORATION (JP) | 2024-02-01 | — | — | US | disclosed |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2023-11-14 | — | — | US | disclosed |
| EP-4252773-A1 | CANCER EXAMINATION METHOD AND CANCER TREATMENT AGENT | Imamitsukai Medical Corporation (JP) | 2023-10-04 | — | — | EP | disclosed |
| WO-2023084449-A1 | DIAMINOCYCLOPENTYLPYRIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS AG (CH) | 2023-05-19 | — | — | WO | disclosed |
| US-20230089867-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | NOVARTIS AG (CH) | 2023-03-23 | — | — | US | disclosed |
| US-11426375-B2 | Substituted bisphenyl butanoic ester derivatives as NEP inhibitors | NOVARTIS AG (CH) | 2022-08-30 | — | — | US | disclosed |
| WO-2022114091-A1 | CANCER EXAMINATION METHOD AND CANCER TREATMENT AGENT | 医療法人 今光会 | 2022-06-02 | — | — | WO | disclosed |
| US-6784184-B2 | FOR THERAPY OF RAS- ONCOGENE-DEPENDENT TUMORS, SUCH AS CANCERS OF PANCREAS, COLON, BLADDER, AND THYROID; USEFUL FOR CONTROLLING METASTASIS, SUPPRESSING ANGIOGENESIS, INDUCING APOPTOSIS, AND RAS-ASSOCIATED PROLIFERATIVE DISEASES | WYETH HOLDINGS CORPORATION | 2004-08-31 | — | — | US | disclosed |
| US-6605628-B1 | Treatment of ras oncogene-dependent tumors; controlling metastasis, suppressing angiogenesis, inducing apoptosis | WYETH HOLDINGS CORPORATION | 2003-08-12 | — | — | US | disclosed |
| EP-0804193-A4 | THIAZOLIDINE DERIVATIVES FOR THE TREATMENT OF PSORIASIS | KURTZ THEODORE W (US) | 2002-03-27 | — | — | EP | disclosed |
| EP-0749430-B1 | THIAZOLIDINEDIONE DERIVATIVES AS ANTI-HYPERGLYCEMIC AGENTS | AMERICAN HOME PROD (US) | 1999-08-25 | — | — | EP | disclosed |
| US-5824694-A | Thiazolidine derivatives for the treatment of psoriasis | BETHESDA PHARMACEUTICALS, INC. (US) | 1998-10-20 | — | — | US | disclosed |
| EP-0804193-A1 | THIAZOLIDINE DERIVATIVES FOR THE TREATMENT OF PSORIASIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-11-05 | — | — | EP | disclosed |
| US-5605918-A | SUBSTITUTED THIAZOLIDINE-2,4-DIONES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-02-25 | — | — | US | disclosed |
| US-5594015-A | Thiazolidine derivatives for the treatment of psoriasis | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-01-14 | — | — | US | disclosed |
| EP-0749430-A1 | THIAZOLIDINEDIONE DERIVATIVES AS ANTI-HYPERGLYCEMIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-12-27 | — | — | EP | disclosed |
| US-5574051-A | HYPOGLYCEMIC | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-11-12 | — | — | US | disclosed |
| WO-1995035108-A1 | THIAZOLIDINE DERIVATIVES FOR THE TREATMENT OF PSORIASIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-12-28 | — | — | WO | disclosed |
| WO-1995024400-A1 | THIAZOLIDINEDIONE DERIVATIVES AS ANTI-HYPERGLYCEMIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | F2 73/4885PRSS1 19/4885PRSS2 151/4885 |
| US-11426375-B2 | Substituted bisphenyl butanoic ester derivatives as NEP inhibitors | MME, REN, ECE1 | F2 4134/4885PRSS1 137/4885PRSS2 719/4885 |
| US-20230089867-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | PCSK9, PCSK7, PCSK6 | F2 133/4885PRSS1 16/4885PRSS2 78/4885 |
| US-12209144-B2 | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | F2 132/4885PRSS1 9/4885PRSS2 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.